Press release
Biosimilar Monoclonal Antibodies Market Latest Report with Forecast to 2031
Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1218
InsightAce Analytic's most recent study indicates that the global market for biosimilar monoclonal antibodies is expected to reach US$4.98 billion in valuation by 2021. With a CAGR of 25% from 2024 to 2031, it is predicted to reach US$36.85 billion by 2030. To produce monoclonal antibodies (mAb), clones of the same immune cell from a single original parent cell are used.
Biosimilar monoclonal antibodies are named thus because every monoclonal antibody produced by a parent cell is similar because they are all clones of the same parent cell. Biosimilars are among the biotherapeutic products. They are on par with state-of-the-art pharmaceutical reference items regarding efficacy, safety, and quality. The complex biological macromolecules known as mAb biosimilars have undergone several post-translational modifications. These biosimilars are helpful in the treatment of a wide range of inflammatory, chronic, and autoimmune diseases.
The global market for biosimilar monoclonal antibodies is expanding due to several factors, including the increasing production of advanced monoclonal antibodies, the ageing population, and the high prevalence of chronic illnesses like kidney failure, cancer, rheumatoid arthritis, psoriasis, diabetes, and others. Over the next few years, more significant opportunities for market expansion are expected as more mAbs' patents expire. Because more of the most widely used antibodies' patents are expiring, demand for mAbs is projected to expand rapidly throughout the forecast period. However, it is anticipated that the difficulty of producing biological pharmaceuticals will hamper the market's growth, the lack of experience with clinical trials, the strict government regulations governing product approvals, and the lack of knowledge among manufacturers regarding the regulation and approval of biosimilars.
Over the projected years, North America is expected to contribute significantly to the market for biosimilar monoclonal antibodies. Regional solid growth can be attributed to attractive reimbursement scenarios, a well-established healthcare infrastructure, and a rise in product approvals. Furthermore, the Asia Pacific regional market is anticipated to have notable growth throughout the estimated period due to an increase in the prevalence of chronic diseases, the demand for reasonably priced treatments, and government financing for the renovation of healthcare facilities.
BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US), and others are some of the prominent market players involved in the Biosimilar Monoclonal Antibodies market.
Recent collaborations and agreements in the market:
• In July 2021, Abzena (UK), a global partner research organization for biologics and bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support third-party biosimilar development. This collaboration resulted in an integrated solution by two prominent service providers in biosimilar development and GMP manufacturing.
• In February 2021, Mylan (US) introduced Ogivri, a trastuzumab biosimilar. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer, previously sold as Herceptin by Genentech.
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1218
Market Segments
Global Biosimilar Monoclonal Antibodies Market, by Product, 2022-2030 (Value US$ Mn)
• Infliximab
• Trastuzumab
• Rituximab
• Adalimumab
• Bevacizumab
• Cetuximab
• Ranibizumab
• Denosumab
• Eculizumab
• Other Pipeline Products
Global Biosimilar Monoclonal Antibodies Market, by Indication, 2022-2030 (Value US$ Mn)
• Oncology
• Inflammatory & Autoimmune Disorders
• Chronic Diseases
• Blood Disorders
• Other Indication
Global Biosimilar Monoclonal Antibodies Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of the prospects for the global Biosimilar Monoclonal Antibodies market
To receive an industry overview and future trends of the Biosimilar Monoclonal Antibodies market
To analyze the Biosimilar Monoclonal Antibodies market drivers and challenges
To get information on the Biosimilar Monoclonal Antibodies market value (US$ Mn) forecast to 2030
Significant investments, mergers & acquisitions in the Biosimilar Monoclonal Antibodies market industry
For More Information @ https://www.insightaceanalytic.com/customisation/1218
Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Monoclonal Antibodies Market Latest Report with Forecast to 2031 here
News-ID: 3452597 • Views: …
More Releases from InsightAce Analytic Pvt.Ltd
Cell and Gene Therapy Supply Chain/Logistics Market Reviews Analysis Report 2024
InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Cell and Gene Therapy Supply Chain/Logistics Market (By Application area (Donor eligibility assessment, Sample collection, Manufacturing, Logistics, Patient verification and treatment follow-up), By Type of software solution (Cell orchestration platform, Enterprise manufacturing system, Inventory management system, Laboratory information management system, Logistics management system, Patient management system, Quality management system,
Tracking and tracing system), By Mode of Deployment…
Preclinical Oncology Models Market - Recent Innovations and Upcoming Trends Anal …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Preclinical Oncology Models Market- by Product (Patient-Derived Xenograft Models (PDX), Cell Line Derived Xenograft Models, Syngeneic Models, Genetically engineered mouse models (GEMMs), Orthotopic Models, Custom Xenograft and Syngeneic Model and Others), Application (Neuroblastoma, Prostate Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Fibrosarcoma, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer and Others),…
2D Materials Market 2024-2031 | Exclusive Study Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global 2D Materials Market Size, Share & Trends Analysis Report By Material (Graphene, Black Phosphorous, Transition Metal Dichalcogenides, Mxenes, Hexagonal Boron Nitride), And End Users (Composite And Coating, Energy Storage Devices, Electronics, Semiconductors, Pharmaceuticals, Automobiles )- Market Outlook And Industry Analysis 2031"
The 2D Materials market will reach over USD 36.27 billion by 2024-2031, exhibiting…
AI in Respiratory Diseases Market Revenue Share Study Analysis Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI in Respiratory Diseases Market- (By Indication (Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Pulmonary Infection), By Imaging Type (MRI, CT Scan, ePRO), By End-use (Hospital, Diagnostic Centers, Ambulatory Surgical centers, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global AI in Respiratory Diseases Market…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…
